A Phase 2 Study of IkT-001Pro in Pulmonary Arterial Hypertension (PAH)
← catalyst calendarNCT06643143 · readout in 315 d
Sponsored by Inhibikase Therapeutics (industry) · IKT — their whole pipeline →.
Phase
Phase 2
Status
Withdrawn
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
0actual
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Study has undergone sponsorship and design changes.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-30 | estimated | When the study began enrolling |
| Primary completion | 2027-06-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-06-30 | estimated | The whole study's end, after follow-up |
| First posted | 2024-10-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-06-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Pulmonary Arterial Hypertension (PAH)
- Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
Interventions
- Drug: IkT-001Pro
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFTo evaluate the effect on PVR in participants with WHO functional class II-III PAH treated with IkT-001Pro compare to placebo
measured Through study completion, an average of 26 weeks with 36 months of extension
To assess the safety and tolerability of two IkT-001Pro doses in PAH
measured Through study completion, an average of 26 weeks with 36 months of extension
Permalink · IKT's whole pipeline · Catalyst calendar · Every registered study · What changed